Loading...

WINDTREE THERAPEUTICS INC Product Launches 8-K Filing

WNDT

WINDTREE THERAPEUTICS INC

()

2024 8-K

Management Change

Convertible Notes Issued

Settlement Announcement

Management Change

Stockholder Meeting Results

Stock Delisting Notice

Product Expansion

Equity Offerings

Equity Offerings

Convertible Promissory Notes

Asset Acquisitions

Voluntary Delisting

Asset Acquisitions

Financial Statements

Asset Acquisitions

Equity Offerings

Board Resignation

Financial Results

Filing Amendment

Capital Structure Change

Stockholder Meeting

Conversion Price Reduction

Director Appointment

Corporate Strategy Update

Nasdaq Compliance Issues

Strategic Advisor Engagement

Financial Results

Management Change

Management Changes

Stock Sale Agreement

Stock Sale Update

Management Change

Investor Update

Positive Clinical Results

Positive Study Results

Annual Meeting Results

Capital Structure Update

Financial Results

Private Placement

Private Placement

Private Offering of Notes

Investor Presentation Update

Common Stock Purchase Agree...

Update Presentation

Reverse Stock Split

Financial Results Announcement

Special Meeting of Stockhol...

Asset Purchase Agreement an...

Resignation of Interim CFO

Engagement of Ladenburg Tha...

Exchange and Termination Ag...

License Agreement with Lee'...

Entry into a Material Defin...

Update Presentation

Equity Incentive Plan Amend...

Financial Results Announcement

Appointment of New Director...

Presentation Update

Financial Results Announcement

Public Offering

Resignation of Chairman

Financial Results

Earnings Reports

External Links:

Windtree Therapeutics announced positive results from its Phase 2b SEISMiC Extension Study of istaroxime for treating early cardiogenic shock due to heart failure on September 25, 2024.

AI Assistant

WINDTREE THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.